###### What this paper adds

-   Previous epidemiological studies of mobile phone use and brain cancer risk have used information on mobile phone use as a proxy measure of exposure to radio frequency fields from mobile phones.

-   Most studies have not observed increased ORs in relation to ever having been a mobile phone user. There were suggestions, however, of an increased risk of glioma in long-term and heavy users, though biases and errors prevent a causal interpretation.

-   The relationship between radio frequency energy absorbed at the tumour location and mobile phone use history is complex. In addition to amount of use, it depends on phone type, network properties, conditions of use and tumour location. The present paper is the first to use estimates of radio frequency energy deposition at the centre of tumours in the brain as a measure of radio frequency dose.

-   An increased risk of glioma was seen in individuals at the highest quintile of radio frequency dose, though reduced risks were seen in the four lower quintiles. When risk was examined as a function of dose received in different time windows before diagnosis, an increasing trend was observed with increasing radio frequency dose (p=0.01) for exposures 7 years or more in the past.

-   Case--case analyses, made possible by tumour localisation, indicated an increased risk in the most exposed region of the brain compared with other areas among long-term users.

-   Patterns of risk for meningioma in relation to radio frequency dose were similar, although increases in risk were much smaller than for glioma, and not statistically significant.

-   Our results suggest that there may be an increase in risk of glioma in the most exposed area of the brain among long-term and heavy users of mobile phones. These results are uncertain (in light of the uncertainties associated with tumour centre localisation, radio frequency dose estimation and sample size) and require replication before they can be taken to indicate a cause--effect relationship.

Introduction
============

Rapid increases in mobile phone use have generated concerns about possible health effects of exposure to radio frequency (RF) electromagnetic fields. A multinational case--control study, Interphone,[@b1] aimed to evaluate the association of brain, acoustic nerve and parotid gland tumours with RF exposure from mobile phone use. Most epidemiological studies, including Interphone, have only reported risk in relation to mobile phone use history.[@b2; @b3; @b4; @b5; @b6; @b7; @b8; @b9; @b10; @b11; @b12; @b13; @b14; @b15; @b16; @b17; @b18; @b19; @b20]

The relationship between RF energy absorbed at the tumour location and mobile phone use history is complex.[@b21; @b22; @b23] In addition to amount of use, it depends on phone type, network properties, conditions of use and tumour location.[@b24] Thus, Interphone attempted a systematic and detailed evaluation and quantification of factors thought to influence RF dose from mobile phones in different brain locations. This necessitated identification of probable determinants of RF Specific Absorption Rate (SAR) during protocol development and questionnaire design and collection and analysis of information to evaluate the importance of each factor. An algorithm was developed to evaluate total RF dose absorbed at specific locations in the brain[@b24] and applied to Interphone study subjects in five countries to estimate RF dose at the tumour location. This paper presents the results of analysis of associations of glioma and meningioma risk with these dose estimates.

Materials and methods
=====================

Analyses used data from the five Interphone countries---Australia, Canada, France, Israel and New Zealand---that agreed to transfer their data to Barcelona when EC, the Interphone Principal Investigator, relocated there. Interphone is an international, population-based case--control study based on a common protocol.[@b1] [@b25]

Definition of cases and controls
--------------------------------

Cases were patients aged 30--59 years with brain glioma or meningioma diagnosed between 2000 and 2004. Cases were ascertained actively from neurosurgical and oncological facilities, and completeness of ascertainment checked through secondary sources.[@b1] All diagnoses were histologically confirmed or based on unequivocal diagnostic imaging.

The original Interphone protocol called for selection of one control per case from a locally appropriate population-based sampling frame. Matching variables were age (within 5 years), sex, region of residence and, in Israel, country of birth. Controls tended to be interviewed later than cases.[@b1] As mobile phone use increased during the study period, later interviews could have spuriously increased exposure prevalence among controls. To minimise resulting bias, controls in all countries were post-hoc matched to cases with tumour localisation using an algorithm that optimised matching on interview time and age within strata defined by sex, region and, in Israel, country of birth. Date of case diagnosis was used as the reference date for cases and controls in each matched set. Each control was assigned the tumour location of his or her matched case as a reference location. To maximise statistical power, all interviewed and eligible controls were matched to glioma and meningioma cases separately, provided they had been interviewed within 1 year of the of the cases\' interview; 1439 controls are thus included in both glioma and meningioma analyses. Number of controls per case varied from 1 to 19 (median 3) for glioma and 1 to 23 (median 2) for meningioma.

Collection of information
-------------------------

Detailed information on past mobile phone use was collected by interview with study subjects or proxies.[@b1] This included amount, timing and conditions of mobile phone use, phone models and operators. A catalogue of phones was used to assist subjects in identifying phones they had used. In each country, historical information was obtained from mobile phone operators on communication systems and frequencies used, introduction of adaptive power control and use of discontinuous transmission.

Tumour localisation
-------------------

Since intracranial RF energy deposition from mobile phones is non-uniform, with most of the energy absorbed near the phone,[@b23] each tumour\'s centre was estimated so that RF dose at that location could be estimated. Neuroradiologists in each centre reviewed radiological images (MRI and CT scans) when possible and recorded tumour location and their best guess at the tumour centre (referred to as 'centre estimated by neuroradiologist') on a generic three-dimensional (3-D) grid map of the human brain, the Gridmaster, made up of 1 cm cubes.[@b26] A detailed methodological description will be published separately.[@b27]

When images were not available, neuroradiologists used radiology reports to prepare a 3-D representation of the tumour volume in the Gridmaster (all cases in Israel and 12% of cases elsewhere) ([table AI](#tblA1){ref-type="table"}). We then developed a computer algorithm to estimate tumour centre (referred to as 'centre estimated by computer algorithm'). For glioma cases, the Euclidean distances from each Gridmaster cube of the tumour\'s 3-D representation to the others were calculated and the cube(s) at the shortest distance(s) from others (the 'centre of gravity') chosen as the centre. For meningioma, tumours were separated into those on the surface of the meninges close to the skull and others. For the second, the process was as described for glioma; for the first, it included only cubes in the outermost Gridmaster layer. The program was validated on subjects for whom a neuroradiologist estimated the centre, with good agreement, particularly for glioma.[@b27]

RF dose algorithm
-----------------

An algorithm was developed to estimate dose as cumulative specific energy (CSE*~l,f,s~*), in joules per kilogram, absorbed at a given location in the brain (*l)* for a given frequency band (*f)* and communication system (*s*) (eg, AMPS, Advanced Mobile Phone System; GSM, Global System for Mobile).[@b24] CSE*~l,f,s~* was calculated as the sum, over all phones the subject used, of the product of estimated average SAR received at the tumour\'s location and total call duration in this frequency band and communication system. Modifying factors were taken into account: laterality of use, hands-free devices, network characteristics and, where appropriate, frequency of use in urban and rural settings. Total cumulative specific energy (TCSE) at the location was then calculated as the sum, over all frequency bands and communication systems, of the frequency- and communication-system-specific CSEs.

If the subject reported a preferred side of use, 90% of phone use was assigned to that side of the head and 10% to the other. If the subject could not answer, or said he or she used it on both sides, 50% of use was assigned to each side.

Statistical analyses
--------------------

Analyses were limited to cases with tumour localisation data. The main analyses used unconditional logistic regression, stratified on the matching variables (age, sex and region) and adjusted for education level and the interaction between study region and time period of interview (6-month intervals). As the matching was on variables that were explicitly measured (and therefore could be controlled in an unconditional analysis), stratified unconditional logistic regression was conducted, rather than conditional logistic regression based on matched sets, to maximise the number of informative strata in the analyses. This was important for analyses by time windows as many matched sets would have been dropped out of these analyses if conditional logistic regression had been used.

For the main analyses, the reference category for ORs was subjects who reported that they had never used mobile phones regularly. Sensitivity analyses restricted to regular users, with the lowest users as the reference category, were also conducted.

Dose variables included TCSE averaged over the estimated tumour centre (generally one to two cubes of the Gridmaster), TCSE averaged over the entire tumour volume and CSE for individual systems defined by frequency band (800--900 and 1800--1900 MHz) and technology type (analogue and digital). In each analysis, TCSE or CSE was censored 1 year before the reference date to allow a minimum latent period between first exposure and tumour diagnosis.

Categorical analyses were conducted in quintiles of TCSE or CSE among regular user controls. In analyses of specific systems, mobile phone users who had not used that system were assigned a CSE of 0 and included in a separate category (eg, 'non 800--900 MHz' for analyses of 800--900 MHz). To allow comparisons with the 13-country Interphone analyses of mobile phone use,[@b28] we also analysed quintiles of cumulative call time (data were too sparse for analyses by deciles).

The main analyses were based on TCSE at the tumour centre estimated by neuroradiologists when available or by computer algorithm and took into account laterality of use. We also assessed the possible effect of RF exposure in different time periods, by fitting a model in which we considered TCSE \<3 years before the reference date, 3--6 years before and 7+ years before, based on reported mobile phone use in these periods. As previous studies have raised the issue of risk 10 years or more after exposure, we originally intended to analyse TCSE in periods 0--4, 5--9 and 10+ years before the reference date but could not because of small numbers of subjects in different TCSE categories in the 10+ years period.

Sensitivity analyses were conducted restricting analyses to subjects with probable centre estimated by a neuroradiologist; not taking into account laterality of phone use (50% of CSE was assigned to each side for all subjects); averaging CSE over the entire tumour volume; and excluding proxy interviews, subjects with very high levels of reported phone use (5 h or more per day in any period) or subjects who reported use of 450 MHz telephones (with little information on spatial SAR distribution, see Cardis *et al*[@b24]).

Finally, case--case analyses were conducted in which mobile phone use was compared between cases whose probable tumour centre was in the most exposed brain region and cases whose tumour centre was elsewhere, using unconditional logistic regression adjusted for age, sex and region. The most exposed area was defined as the area with the highest RF SAR from mobile phones,[@b23] falling within the 3 dB exposure volume ([figure AI](#figA1){ref-type="fig"}), without taking into account reported laterality of use or self-reported amount of mobile phone use. It comprised 230 of the 1431 Gridmaster cubes, a region comprising about 16% of the brain volume and absorbing over 50% of the SAR from mobile phones.

Results
=======

The five Interphone countries contributing to this analysis ascertained 1302 cases of glioma, 1199 cases of meningioma and 4838 controls eligible for the study ([table AI](#tblA1){ref-type="table"}).[@b1] Of these, 809 glioma cases and 842 meningioma cases were interviewed and could be matched to at least one control ([table AI](#tblA1){ref-type="table"}). Information on tumour localisation, communication systems and frequency bands used was available for 553 glioma cases (42.4% of glioma cases) and 1762 matched controls (36% of controls), and 676 meningioma cases (56.4% of meningioma cases) and 1911 matched controls (39.5% of controls); these were the subjects of the primary analyses of RF exposure. The mean age of glioma cases was 47.2 years and 62% were men; the mean age of meningioma cases was 49.7 years and 26% were men. The respective matched controls had similar age and sex distributions.

We calculated ORs for regular phone use and cumulative call time without use of hands-free devices in all interviewed subjects who could be matched to relate results of this five-country analysis to those of Interphone as a whole.[@b28] For glioma, the OR for regular phone use was 0.92 (95% CI 0.75 to 1.13) and that for the top category of cumulative call time (735+ h of use) was 1.17 (95% CI 0.88 to 1.56) ([table 1](#tbl1){ref-type="table"}). The most closely corresponding Interphone results were, respectively, 0.81 (95% CI 0.70 to 0.94) and, for 735--1639.9 and 1640+ h of use together, 1.00 (95% CI 0.80 to 1.22). For meningioma, the OR for regular phone use was 0.80 (95% CI 0.66 to 0.96) and that for 735+ h of use was 1.01 (95% CI 0.75 to 1.36) ([table 1](#tbl1){ref-type="table"}) compared with Interphone results of, respectively, 0.79 (95% CI 0.68 to 0.91) and, for 735--1639.9 and 1640+ h of use together, 0.93 (95% CI 0.73 to 1.19). Results of similar analyses in subjects with localisation data were not greatly different from those in all interviewed subjects ([table 1](#tbl1){ref-type="table"}). ORs for glioma in subjects whose tumour centre was also estimated by a neuroradiologist were higher---1.06 (95% CI 0.77 to 1.47) in regular users and 1.72 (95% CI 1.07 to 2.77) in 735+ h of call time, mainly due to exclusion of subjects from Israel. Israel contributed 73% of excluded glioma cases and its ORs for glioma were 0.67 (95% CI 0.43 to 1.05) in regular users and 0.57 (95% CI 0.30 to 1.74) in 735+ h of call time.

###### 

ORs for brain tumours with regular use of a mobile phone and cumulative mobile phone call time in all eligible subjects, subjects with tumour localisation data and subjects with tumour centre estimated by a neuroradiologist[\*](#table-fn1){ref-type="table-fn"}

                                                        All subjects matched to controls or case interviewed within 1 year   Subjects with tumour centre estimated by a neuroradiologist or computer algorithm[†](#table-fn2){ref-type="table-fn"}   Only subjects with tumour centre estimated by a neuroradiologist                                                  
  ----------------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ----- ------ --------------------- ----- ----- ---------------------
  Glioma                                                                                                                                                                                                                                                                                                                                                               
  Regular use                                                                                                                                                                                                                                                                                                                                                          
   Never regular user                                   266                                                                  834                                                                                                                     1.00                                                               196   617    1.00                  117   361   1.00
   Regular user                                         542                                                                  1629                                                                                                                    0.92 (0.75 to 1.13)                                                355   1103   0.93 (0.73 to 1.18)   209   565   1.06 (0.77 to 1.47)
  Cumulative call time without hands-free devices (h)                                                                                                                                                                                                                                                                                                                  
   Never regular user                                   266                                                                  834                                                                                                                     1.00                                                               196   617    1.00                  117   361   1.00
   \<13.0                                               69                                                                   234                                                                                                                     0.88 (0.63 to 1.24)                                                44    174    0.83 (0.55 to 1.26)   25    102   0.81 (0.46 to 1.42)
   13.0--60.9                                           103                                                                  327                                                                                                                     0.93 (0.69 to 1.25)                                                68    223    0.93 (0.65 to 1.32)   46    134   1.11 (0.71 to 1.75)
   61.0--199.9                                          110                                                                  383                                                                                                                     0.74 (0.55 to 0.99)                                                63    264    0.66 (0.46 to 0.96)   39    136   0.81 (0.5 to 01.33)
   200--734.9                                           123                                                                  367                                                                                                                     0.94 (0.71 to 1.26)                                                90    237    1.07 (0.76 to 1.50)   46    110   1.03 (0.64 to 1.67)
   735+                                                 137                                                                  318                                                                                                                     1.17 (0.88 to 1.56)                                                90    205    1.25 (0.88 to 1.77)   53    83    1.72 (1.07 to 2.77)
  Meningioma                                                                                                                                                                                                                                                                                                                                                           
  Regular use                                                                                                                                                                                                                                                                                                                                                          
   Never regular user                                   356                                                                  807                                                                                                                     1.00                                                               294   643    1.00                  157   398   1.00
   Regular user                                         486                                                                  1 541                                                                                                                   0.80 (0.66 to 0.96)                                                381   1153   0.77 (0.63 to 0.95)   186   648   0.77 (0.58 to 1.03)
  Cumulative call time without hands-free devices (h)                                                                                                                                                                                                                                                                                                                  
   Never regular user                                   356                                                                  807                                                                                                                     1.00                                                               294   643    1.00                  157   398   1.00
   \<13.0                                               102                                                                  247                                                                                                                     0.86 (0.64 to 1.15)                                                80    198    0.84 (0.60 to 1.16)   43    117   0.87 (0.56 to 1.34)
   13.0--60.9                                           101                                                                  301                                                                                                                     0.79 (0.60 to 1.04)                                                82    225    0.80 (0.59 to 1.10)   46    137   0.80 (0.53 to 1.22)
   61.0--199.9                                          97                                                                   347                                                                                                                     0.71 (0.53 to 0.94)                                                73    257    0.64 (0.46 to 0.89)   35    156   0.61 (0.39 to 0.96)
   200--734.9                                           89                                                                   349                                                                                                                     0.69 (0.51 to 0.93)                                                67    265    0.63 (0.45 to 0.88)   29    141   0.57 (0.35 to 0.94)
   735+                                                 97                                                                   297                                                                                                                     1.01 (0.75 to 1.36)                                                79    208    1.06 (0.75 to 1.48)   33    97    1.30 (0.79 to 2.15)

Analyses based on unconditional logistic regression stratified on age, sex and region and adjusted for education and timing of interview.

Origin is as estimated by a neuroradiologist when available or as estimated by computer algorithm otherwise.

TCSE was highly skewed in cases and controls ([figure AII](#figA2){ref-type="fig"}). Higher proportions of glioma cases than controls had TCSE above 3500 J/kg. Though there was moderate agreement between categorisation of subjects by TCSE and cumulative call time (weighted κ 0.68), misclassification was non-negligible, particularly at higher frequency bands.[@b24] ORs for glioma and meningioma were below 1 in the first four quintiles of TCSE. In the highest quintile, the OR for glioma was 1.35 (95% CI 0.96 to 1.90) in subjects with tumour localisation and 1.66 (95% CI 1.03 to 2.67) in subjects with centre estimated by a neuroradiologist ([table 2](#tbl2){ref-type="table"}). Corresponding ORs for meningioma were 0.90 (95% CI 0.66 to 1.24) and 1.01 (95% CI 0.63 to 1.62).

###### 

ORs for brain tumours with level of total cumulative specific radio frequency energy (total cumulative specific energy) (in joules per kilogram)[\*](#table-fn3){ref-type="table-fn"}

                        Subjects with tumour centre estimated by a neuroradiologist or computer algorithm[†](#table-fn4){ref-type="table-fn"}   Only subjects with tumour centre estimated by a neuroradiologist                                     
  --------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ --------------------- ----- ----- ---------------------
  Glioma                                                                                                                                                                                                                                             
   Never regular user   196                                                                                                                     617                                                                1.00                  117   361   1.00
   \<76.7               67                                                                                                                      265                                                                0.76 (0.53 to 1.09)   36    150   0.84 (0.51 to 1.36)
   76.7--               68                                                                                                                      227                                                                0.94 (0.66 to 1.35)   43    128   1.00 (0.62 to 1.60)
   284.1--              60                                                                                                                      207                                                                0.80 (0.54 to 1.18)   39    102   1.15 (0.69 to 1.90)
   978.9--              57                                                                                                                      197                                                                0.89 (0.61 to 1.30)   34    99    0.92 (0.55 to 1.53)
   3123.9+              103                                                                                                                     207                                                                1.35 (0.96 to 1.90)   57    86    1.66 (1.03 to 2.67)
  Meningioma                                                                                                                                                                                                                                         
   Never regular user   294                                                                                                                     643                                                                1.00                  156   396   1.00
   \<76.7               103                                                                                                                     261                                                                0.90 (0.67 to 1.21)   51    150   0.86 (0.57 to 1.29)
   76.7--               71                                                                                                                      199                                                                0.74 (0.53 to 1.04)   47    127   0.95 (0.62 to 1.44)
   284.1--              56                                                                                                                      233                                                                0.56 (0.39 to 0.80)   29    136   0.53 (0.32 to 0.87)
   978.9--              62                                                                                                                      209                                                                0.72 (0.51 to 1.02)   23    117   0.55 (0.32 to 0.93)
   3123.9+              88                                                                                                                      251                                                                0.90 (0.66 to 1.24)   35    114   1.01 (0.63 to 1.62)

Analyses based on unconditional logistic regression stratified on age, sex and region and adjusted for education and timing of interview.

Centre is as estimated by a neuroradiologist when available or as estimated by computer algorithm otherwise.

In analyses of TCSE in different time intervals before the reference date, an increased OR was seen for glioma in the highest category of TCSE 7+ years before diagnosis (OR 1.91, 95% CI 1.05 to 3.47), with an irregular but reasonably consistent trend across TCSE categories (p=0.01). There was no evidence of increased risk for more recent exposures. Results for meningioma were similar, but without evidence of a trend with TCSE for exposure 7+ years before diagnosis (p=0.24) ([table 3](#tbl3){ref-type="table"}).

###### 

ORs for glioma and meningioma with level of total cumulative specific energy exposure (in joules per kilogram) in different windows of time before diagnosis of the case in subjects with probable tumour centre estimated by a neuroradiologist or computer algorithm*[\*](#table-fn5){ref-type="table-fn"}*

                                            Glioma   Meningioma                                      
  ----------------------------------------- -------- ------------ --------------------- ----- ------ ---------------------
  \<3 years in the past                                                                              
   Never regular user in this time period   206      647          1.00                  300   667    1.00
   \<76.7                                   111      350          0.88 (0.61 to 1.26)   128   353    0.81 (0.59 to 1.11)
   76.7--                                   72       271          0.63 (0.41 to 0.96)   84    252    0.79 (0.54 to 1.14)
   284.1--                                  75       224          0.73 (0.46 to 1.16)   67    259    0.69 (0.46 to 1.04)
   978.9--                                  40       141          0.56 (0.32 to 0.99)   51    144    0.92 (0.57 to 1.47)
   3123.9+                                  47       87           1.29 (0.68 to 2.47)   46    126    0.86 (0.49 to 1.53)
  3--6 years in the past                                                                             
   Never regular user in this time period   270      917          1.00                  417   962    1.00
   \<76.7                                   60       218          1.05 (0.69 to 1.61)   79    211    1.09 (0.75 to 1.56)
   76.7--                                   64       170          1.36 (0.88 to 2.11)   41    168    0.73 (0.46 to 1.15)
   284.1--                                  51       167          1.04 (0.62 to 1.75)   45    180    0.93 (0.58 to 1.50)
   978.9--                                  49       132          1.14 (0.65 to 2.01)   48    132    1.08 (0.65 to 1.78)
   3123.9+                                  57       116          0.97 (0.49 to 1.93)   46    148    0.76 (0.40 to 1.43)
  7+ years in the past                                                                               
   Never regular user in this time period   421      1445         1.00                  586   1493   1.00
   \<76.7                                   20       63           1.11 (0.61 to 2.02)   28    81     1.07 (0.64 to 1.78)
   76.7--                                   23       53           1.53 (0.85 to 2.78)   8     49     0.74 (0.33 to 1.67)
   284.1--                                  24       53           1.50 (0.81 to 2.78)   17    68     0.88 (0.47 to 1.64)
   978.9--                                  25       49           1.69 (0.91 to 3.13)   16    59     1.00 (0.52 to 1.92)
   3123.9+                                  38       57           1.91 (1.05 to 3.47)   21    51     2.01 (1.03 to 3.93)

Unconditional logistic regression analyses stratified on age, sex and region and adjusted for education and timing of interview. Centre is taken to be as estimated by a neuroradiologist where available and as estimated by computer algorithm otherwise. Associations in each time window are adjusted for associations in each other window.

[Table 4](#tbl4){ref-type="table"} shows the results of sensitivity analyses for associations of brain tumours with the highest quintile of TCSE. Using tumour centre estimated by computer algorithm for all subjects had little impact on the results. The ORs for glioma and meningioma fell slightly when reported laterality was not taken into account. Excluding subjects with improbable reported use (\>5 h/day) or with reported use of 450 MHz phones had no effect on ORs in the highest quintile, while excluding subjects with proxy interviews increased them slightly, particularly for glioma. The OR in the highest quintile was greatest in analyses excluding non-regular users (using the lowest quintile of TCSE as the reference category---see also [table AII](#tblA2){ref-type="table"}) and analyses restricted to subjects for whom images were available for tumour localisation.

###### 

Results of sensitivity analyses on ORs for glioma and meningioma with radio frequency exposure in the highest quintile of total cumulative specific energy (TCSE)

  Factors included in sensitivity analyses                                                                                               Glioma   Meningioma                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------- -------- ------------ ---------------------------------------------------------- ---- ----- ---------------------
  All subjects with tumour localisation                                                                                                                                                                                              
   TCSE at centre of tumour                                                                                                                                                                                                          
    Estimated by neuroradiologists when available, predicted by computer algorithm otherwise---main analysis                             103      207          1.35 (0.96 to 1.90)                                        88   251   0.90 (0.66 to 1.24)
    Predicted by computer algorithm for all subjects                                                                                     99       206          1.32 (0.93 to 1.86)                                        93   253   0.93 (0.68 to 1.27)
    Estimated by neuroradiologists when available, predicted by computer algorithm otherwise *not taking account of tumour laterality*   105      241          1.23 (0.89 to 1.72)                                        94   288   0.84 (0.62 to 1.15)
   TCSE averaged over the entire tumour                                                                                                                                                                                              
    Taking into account reported tumour laterality                                                                                       107      224          1.28 (0.92 to 1.80)                                        93   253   0.92 (0.69 to 1.24)
    Not taking into account tumour laterality                                                                                            111      254          1.21 (0.87 to 1.68)                                        94   291   0.84 (0.61 to 1.15)
   Effect of exclusion of                                                                                                                                                                                                            
    Subjects with very high reported use (\>5 h/day)                                                                                     93       188          1.34 (0.94 to 1.91)                                        81   235   0.91 (0.66 to 1.26)
    Subjects with proxy response                                                                                                         94       207          1.43 (0.99 to 2.05)                                        87   249   0.93 (0.68 to 1.27)
    Subjects reporting use of 450 MHz telephones                                                                                         101      202          1.35 (0.96 to 1.91)                                        88   246   0.92 (0.67 to 1.26)
    Never regular users (using the lowest quintile of TCSE as reference category)                                                        103      195          1.93 (1.26 to 2.96)                                        88   237   1.04 (0.71 to 1.53)
   By frequency band                                                                                                                                                                                                                 
    800--900 MHz                                                                                                                         100      197          1.36 (0.96 to 1.93)                                        88   240   1.35 (0.74 to 2.44)
    1800--1900 MHz                                                                                                                       22       57           1.45[\*](#table-fn6){ref-type="table-fn"} (0.80 to 2.63)   6    59    0.28 (0.10 to 0.79)
   By communication system                                                                                                                                                                                                           
    Analogue                                                                                                                             43       82           1.22 (0.77 to 1.92)                                        27   109   1.29 (0.71 to 2.34)
    Digital                                                                                                                              79       194          1.22 (0.84 to 1.76)                                        87   214   0.87 (0.45 to 1.67)
  Only subjects with centre estimated by neuroradiologists                                                                                                                                                                           
   Using centre estimated by neuroradiologist                                                                                            57       86           1.66 (1.03 to 2.67)                                        35   114   1.01 (0.63 to 1.62)
   Using centre predicted by computer algorithm for all subjects                                                                         53       85           1.58 (0.98 to 2.57)                                        39   118   1.02 (0.64 to 1.61)
  Only subjects for whom images were available (ie, excluding Israel)                                                                    70       109          1.82 (1.20 to 2.76)                                        33   113   1.23 (0.76 to 2.00)
  Country-specific estimates                                                                                                                                                                                                         
   Australia                                                                                                                             30       49           1.15 (0.56 to 2.38)                                        19   67    0.75 (0.38 to 1.48)
   Canada                                                                                                                                21       27           3.48 (1.63 to 7.43)                                        7    33    1.51 (0.58 to 3.93)
   France                                                                                                                                11       29           1.39 (0.56 to 3.49)                                        7    29    0.77 (0.30 to 1.98)
   Israel                                                                                                                                33       98           0.74 (0.40 to 1.37)                                        50   116   0.74 (0.47 to 1.17)
   New Zealand                                                                                                                           8        4            3.69 (0.78 to 17.5)                                        5    6     5.52 (0.98 to 31.2)
  Sex-specific estimates                                                                                                                                                                                                             
   Men                                                                                                                                   85       133          1.33 (0.87 to 2.03)                                        41   151   0.98 (0.58 to 1.65)
   Women                                                                                                                                 18       74           1.30 (0.69 to 2.47)                                        47   100   0.88 (0.58 to 1.34)

OR in fourth quintile: 1.86, 95% CI 1.07 to 3.22 (29 cases and 54 controls).

Considering frequency band and technology type (analogue or digital) ([table 4](#tbl4){ref-type="table"}), ORs were increased somewhat for glioma in the highest quintile of CSE in the 800--900 MHz frequency range and the highest two quintiles in the 1800--1900 MHz range. The OR for meningioma was also elevated in the highest quintile in the 800--900 MHz range, but much reduced in the highest quintile in the 1800--1900 MHz range. There was little evidence of increased risk when considering analogue and digital technologies separately, except possibly for analogue signals with meningioma. These analyses are not independent, however, as many subjects had used several different frequency bands or technologies. Data were too sparse for meaningful analyses of subjects who only used one frequency band or system. ORs for glioma were above 1 in all countries except Israel; CIs were wide; however, the p value for heterogeneity across countries was 0.37. Country-specific ORs for meningioma were more variable. There was little evidence of differences in ORs between men and women.

For the case--case analyses, there were 44 glioma cases and 135 meningioma cases located in the most exposed area of the brain and 512 and 537 cases, respectively, located elsewhere. Knowledge of SAR was used to define the two case groups, thus only mobile phone use was compared between them. The ORs for glioma in the highest exposed area were higher in long-term users than in short-term users (OR 2.80, 95% CI 1.13 to 6.94 for 10 years or more of use). While OR for glioma tended to increase with increasing call time to the fourth quintile, it was 0.99 in the highest quintile ([table 5](#tbl5){ref-type="table"}). For meningioma, ORs were highest in long-term and heavy users, but CIs were wide.

###### 

Results of case--case analyses of glioma and meningioma by time since start of use of mobile phones and cumulative call time comparing cases[\*](#table-fn7){ref-type="table-fn"} originating in the region of the brain within the 3 dB exposure volume (∼16% of brain volume receiving 50% of the total absorbed energy) to cases[†](#table-fn8){ref-type="table-fn"} originating in other areas of the brain[‡](#table-fn9){ref-type="table-fn"}

                                                        Glioma   Meningioma                                    
  ----------------------------------------------------- -------- ------------ --------------------- ---- ----- ---------------------
  Regular user                                                                                                 
   Never regular user                                   14       178          1.00                  66   221   
   Ever regular user                                    30       334          1.35 (0.64 to 2.87)   69   316   0.74 (0.49 to 1.11)
  Time since start of use (years)                                                                              
   Never regular user                                   14       178          1.00                  66   221   1.00
   1--4                                                 12       133          1.37 (0.59 to 3.19)   38   179   0.67 (0.41 to 1.07)
   5--9                                                 7        147          0.72 (0.27 to 1.90)   22   112   0.75 (0.42 to 1.34)
   10+                                                  11       54           2.80 (1.13 to 6.94)   9    25    1.34 (0.55 to 3.25)
  Cumulative call time without hands-free devices (h)                                                          
   Non-regular                                          14       178          1.00                  66   221   1.00
   \<39                                                 6        65           1.19 (0.40 to 3.51)   16   97    0.55 (0.29 to 1.02)
   39--                                                 4        67           0.93 (0.27 to 3.14)   21   78    0.93 (0.51 to 1.68)
   220--                                                5        68           1.38 (0.42 to 4.53)   9    52    0.52 (0.23 to 1.14)
   520--                                                10       66           2.55 (0.94 to 6.91)   10   52    0.67 (0.30 to 1.48)
   1147+                                                5        68           0.99 (0.30 to 3.27)   13   37    1.41 (0.66 to 3.02)

Treated as 'cases'.

Treated as 'controls'.

Quintiles of cumulative call time among 'controls' (glioma cases with tumour centre outside the most exposed area). Centre is as estimated by a neuroradiologist when available or as estimated by computer algorithm otherwise. Unconditional logistic regression analyses were done, stratified on age, sex and region and adjusted for education and timing of interview.

Discussion
==========

We have presented results of a first attempt to analyse brain tumour risk in relation to amount of RF absorbed by the brain from use of a mobile phone held to the ear. In principle, a measure of absorbed RF should be a more accurate indicator of RF exposure to neural tissue than just mobile phone use and enhance our ability to detect causal associations that might exist between exposure to mobile phone RF fields and brain tumours. Although our estimate of RF dose takes into account reported phone use (which is subject to recall bias and uncertainties[@b28]), it also incorporates objective parameters (location of tumour, frequency band and characteristics of communication systems), not influenced by the interviewees recall, which affect the amount of RF energy received at the tumour location.[@b24] The localisation of tumours, necessary for accurate estimation of relevant RF absorption, made our case--case analysis by regions of the brain possible.

Overall, there was weak evidence of stronger associations of glioma and meningioma when a comprehensive estimate of RF dose rather than just mobile phone use was used in the case--control analysis. For glioma, the OR for the highest quintile of TCSE was 1.35; that for the highest quintile of cumulative call time was 1.25. There was a similar pattern for meningioma. There are several possible explanations for this comparative lack of increase in ORs using TCSE: observations of increased brain tumour risk with mobile phone use are due to biases, and there is no true association between mobile phone RF and brain tumours; the associations of brain tumours with TCSE are greatly weakened by sources of uncertainty in our dose estimates; or a metric other than the absorbed energy better reflects the carcinogenic mechanism.[@b24] Furthermore, the small increases observed could be due to confounding of RF absorption with pulsed extremely low frequency (ELF) magnetic fields from digital phones.[@b24] There is little support for this, though, when we compare ORs for analogue and digital systems ([table 4](#tbl4){ref-type="table"}) or in our case--case analyses in which the most exposed region was defined on the basis of RF absorption, which is much more localised than ELF absorption. With respect to the performance of TCSE as a dose measure, it should be noted that while cumulative call time contributed to the calculation of TCSE and there was moderate agreement between the two measures, there was important residual variation due to the inclusion of measures of RF absorption in TCSE.[@b24] It is thus possible that investigation of different dose metrics and quantification of related uncertainties may yet improve RF dose estimation.[@b24]

The results of our case--case analysis show a moderately strong association of glioma with mobile phone use that started 10+ years before diagnosis, OR 2.80, and little increase with shorter latency. Because of the nature of the case--case analyses, bias due to differential participation of cases and controls is ruled out; systematic differences in recall between cases with tumours in the heavily exposed region of the brain and those with tumours in the less heavily exposed region seem improbable since cases are not aware of exact tumour location and its meaning regarding exposure. The comparatively small number of subjects from five countries on which this analysis is based makes the results of the present case--case analysis much more uncertain than they would be if based on Interphone as a whole.

We also observed evidence of increased glioma risk with a long latent period after first use of a mobile phone in our standard case--control study analysis. The OR for glioma in the highest quintile of TCSE was 1.91 for exposure beginning 7+ years in the past (numbers of subjects by quintile of TCSE were too small for meaningful analyses of exposures 10+ years in the past), and there was evidence of a trend towards increasing risk with increasing exposure. Lack of such a trend has been a consistent feature of Interphone analyses of risk of glioma and may suggest that increased ORs in the highest cumulative mobile phone use category are due to observed greater overestimation of more distant past mobile phone use by cases than controls.[@b29] The apparent dose--response relationship for exposure 7+ years ago, however, suggests that bias is not a sufficient explanation for the increased OR in the highest TCSE category, at least in this exposure period, and suggests that the increased OR seen in the highest category of use in the Interphone report is valid. These results also suggest that if there is a real effect of RF on brain tumour risk, a combination of a minimum latent period and amount of exposure may be needed for an increased risk to be observable (it is of note that the highest category of use in this study, 735 h or more corresponds to about 12--13 min of use a day over 10 years).

A number of case--control studies, including Interphone,[@b28] have reported stronger associations with phone use on the side of the head with the tumour. We dealt with exposure laterality in the present analysis by allocating 90% of reported phone use to the preferred side of phone use and 10% to the other side when there was a preferred side (87% of cases and 91% of controls); otherwise, 50% was allocated to each side. In a sensitivity analysis in which we allocated 50% to each side in all subjects, the ORs for glioma and meningioma in the highest quintile of TCSE averaged over the whole tumour were only slightly reduced ([table 4](#tbl4){ref-type="table"}). Like comparisons of ORs for RF absorption with cumulative mobile phone use, this lack of marked change in OR may indicate that estimation of RF absorption has not greatly improved overall exposure ascertainment in this study. It also suggests that the increased glioma ORs are not sensitive to errors in recall of laterality of mobile phone use, which is suggested also by our case--case analyses in which laterality of use was not taken into account.

Associations observed with higher levels of TCSE exposure are much weaker for meningioma than glioma, being barely evident with TCSE in the case--control analyses except in the highest category in those first exposed 7+ years before diagnosis ([table 3](#tbl3){ref-type="table"}). The ORs for meningioma in intermediate TCSE exposure categories are also sometimes much less than those for glioma ([tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}) and below unity. We have no certain explanation for these differences, except that they could suggest biases affecting results for both tumours (more for meningioma), a causal association of mobile phone RF with both (stronger for glioma than for meningioma) or, perhaps, a shorter latency for glioma occurrence.

A major strength of this paper is improved ascertainment of relevant exposure, which we presume to be mobile phone RF energy absorbed at the tumour location when the phone is in use near the ear. It is a weakness, though, that tumour localisation was only available for about half the cases. Small increases in strengths of associations when comparing results for TCSE with those for cumulative phone use suggest that there was a small increase in measurement accuracy (assuming a causal association) from estimation of RF dose at the tumours\' centres. This suggestion is supported by the further increases in ORs when only tumours for which a neuroradiologist had estimated the centre were included in analyses. However, this analysis excluded Israeli subjects, for which the OR for any use of a mobile phone was less than that for the other four centres (OR without Israel 1.06), which weakens this inference. Furthermore, when neuroradiologists estimates of the centre were replaced by computer generated estimates, the OR for glioma in the highest category of TCSE fell only from 1.66 to 1.58. Thus neuroradiologists\' localisations of the centre at the tumour\'s centre of gravity may have been no more accurate than the computer algorithms.

The association of glioma with estimated TCSE seemed to be robust against subjects\' recall of implausibly high mobile phone use: exclusion of those with use \>5 h reduced the OR minimally from 1.35 to 1.34. In contrast, in Interphone as a whole, the reduction was from 1.40 to 1.27. While this difference might be due to different exposure measures, it could also be due to the use of a subset of Interphone countries in this analysis.

Generally speaking, results of our analyses are similar to comparable analyses based on all Interphone centres.[@b28] One other study, from Sweden, has investigated associations of mobile phone use with brain tumour risk based on tumours diagnosed over a period, 2000 to 2003, nearly the same as Interphone, 2000 to 2004.[@b9] That study found increased risks of malignant brain tumours (mostly gliomas) with any use of analogue or digital mobile phones or cordless phones; risk was generally increased in both low- and high-exposure categories, evident with exposure 1--5 years before diagnosis and increasing with intensity of exposure in time intervals more distant from diagnosis. Our results are different from this study\'s results with respect to the apparent limitation of an association between exposure and glioma in our data to higher exposures and exposures occurring 7+ or 10+ years before diagnosis.

Our use of estimates of RF energy absorbed in the brain as indicators of dose in analyses of associations of brain tumour occurrence with mobile phone use may have increased the strength of some positive associations otherwise observable between these tumours and estimated cumulative use of a mobile phone. Although subject to considerable uncertainty, our analyses suggest that there is an increase in glioma risk with higher levels of RF dose in people whose brain has absorbed high levels of RF energy from mobile phone use and that this risk may only be evident in people who began mobile phone use 7--10 years or more before diagnosis. There is a possibility also of similar, but apparently much smaller, increases in meningioma risk. Uncertainties around these results require that they are replicated before they can be considered to be real. The best way to replicate them would be to repeat this analysis in data from the other eight Interphone countries and in future studies with longer latency periods and higher cumulative exposures.
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###### 

Distributions of glioma and meningioma cases and controls ascertained, interviewed and matched and with data available for analysis

  Glioma                                                   
  -------------- ------ ------ ------ ------ ------ ------ -----
  Cases                                                    
   Total         1302   829    809    567    553    339    329
   Australia     536    301    295    142    142    141    141
   Canada        273    170    170    158    144    110    100
   France        155    94     94     68     68     56     56
   Israel        206    180    168    163    163    0      0
   New Zealand   132    84     82     36     36     32     32
  Controls                                                 
   Total         4838   2565   2496   1877   1762   1032   958
   Australia     1608   669    669    328    317    327    316
   Canada        1330   653    633    581    492    348    296
   France        639    472    459    331    328    294    291
   Israel        911    599    587    566    562    0      0
   New Zealand   350    172    148    71     63     63     55

  Meningioma                                               
  -------------- ------ ------ ------ ------ ------ ------ ------
  Cases                                                    
   Total         1199   895    842    688    676    349    343
   Australia     413    254    250    158    158    155    155
   Canada        134    94     94     82     71     56     50
   France        190    145    144    116    116    109    109
   Israel        390    350    306    303    302    0      0
   New Zealand   72     52     48     29     29     29     29
  Controls                                                 
   Total         4838   2565   2464   2015   1911   1213   1142
   Australia     1608   669    667    431    413    417    400
   Canada        1330   653    613    540    466    342    295
   France        639    472    458    379    376    358    356
   Israel        911    599    591    569    565    0      0
   New Zealand   350    172    135    96     91     96     91

###### 

ORs for brain tumours with level of total cumulative specific RF energy (TCSE) exposure (in joules per kilogram) in subjects with tumour centre estimated by a neuroradiologist or computer algorithm, excluding non-regular users. n these analyses, the lowest quintile of TCSE is used as the reference category

               Subjects with tumour centre estimated by a neuroradiologist or computer algorithm         
  ------------ ----------------------------------------------------------------------------------- ----- ---------------------
  Glioma                                                                                                 
   \<76.7      65                                                                                  241   1.00
   76.7--      68                                                                                  213   1.34 (0.86 to 2.08)
   284.1--     60                                                                                  198   1.13 (0.71 to 1.79)
   978.9--     57                                                                                  191   1.22 (0.77 to 1.93)
   3123.9+     103                                                                                 195   1.93 (1.26 to 2.96)
  Meningioma                                                                                             
   \<76.7      96                                                                                  231   1.00
   76.7--      71                                                                                  194   0.86 (0.58 to 1.27)
   284.1--     56                                                                                  221   0.63 (0.41 to 0.95)
   978.9--     62                                                                                  199   0.87 (0.58 to 1.31)
   3123.9+     88                                                                                  237   1.04 (0.71 to 1.53)

![Spatial deposition of radio frequency (RF) energy in the Gridmaster cells---the light cubes identify the most exposed region of the brain, that is, that with the highest specific absorption rate of RF energy from mobile phones. The dark cubes identify the less exposed area of the brain. The most exposed area (light cubes) correspond to about 16% of the brain volume and absorbs \>50% of the total RF energy in the brain from mobile phones used at the ear.](oemed-2011-100155fig1){#figA1}

![Distribution of glioma cases and controls by level of total cumulative specific energy (TCSE) (in joules per kilogram) at the estimated centre of the tumour; centre is taken to be as estimated by neuroradiologist, where available, and as estimated by computer algorithm otherwise.](oemed-2011-100155fig2){#figA2}
